drugset / Trial / NCT05332678
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open-label, proof-of-concept study to evaluate the safety and treatment effects of SLS-005 in Participants with Alzheimer's Disease (AD) treated once or twice weekly for 52 weeks.
Timeline
- Start
- 2023-03-03
- Primary completion
- 2023-04-10
- Completion
- 2023-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SLS-005 | Unknown | 0.75 g/kg | Intravenous |